| 0.2815 -0.017 (-5.74%) | 03-19 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.47  |
1-year : | 0.57 |
| Resists | First : | 0.4 |
Second : | 0.48 |
| Pivot price | 0.33 |
|||
| Supports | First : | 0.27 |
Second : | 0.22 |
| MAs | MA(5) : | 0.3 |
MA(20) : | 0.33 |
| MA(100) : | 0.48 |
MA(250) : | 4.09 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 23 |
D(3) : | 29.7 |
| RSI | RSI(14): 30.8 |
|||
| 52-week | High : | 32 | Low : | 0.27 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ITOC ] has closed below the lower bollinger band by 7.1%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ ITOC ] is to continue within current trading range. It is unclear right now based on current values. 47.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 11 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.3 - 0.3 | 0.3 - 0.31 |
| Low: | 0.27 - 0.27 | 0.27 - 0.27 |
| Close: | 0.28 - 0.28 | 0.28 - 0.29 |
iTonic Holdings Ltd., a healthcare solutions provider, develops and commercializes treatment software and devices used for brachytherapy. Its proprietary treatment planning system is a radioactive particle implantation, a radiotherapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors. The company offers FTTPS, a treatment planning system for treating various malignant tumors, which could determine the target volume, prescription dose, and dose limitation to protect organs at risks and produce dose distribution plan for brachytherapy for cancer patients. The company was formerly known as Pheton Holdings Ltd and changed its name to iTonic Holdings Ltd. in January 2026. iTonic Holdings Ltd. was founded in 1998 and is headquartered in Beijing, China. iTonic Holdings Ltd. operates as a subsidiary of ZJW (BVI) LTD.
Thu, 19 Mar 2026
Zhixin Li Net Worth (2026) - GuruFocus
Mon, 16 Mar 2026
iTonic Holdings (ITOC) director Zhang Pengfei files initial Form 3 ownership - Stock Titan
Mon, 16 Mar 2026
CFO Li Zhixin files initial insider ownership Form 3 for iTonic (ITOC) - Stock Titan
Tue, 10 Feb 2026
ITOC Stock Price, News & Analysis - Stock Titan
Tue, 10 Feb 2026
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Sat, 17 Jan 2026
symbol__ Stock Quote Price and Forecast - CNN
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Specialties
|
|
| Shares Out | 0 (M) |
| Shares Float | 9 (M) |
| Held by Insiders | 7.45e+006 (%) |
| Held by Institutions | 20.5 (%) |
| Shares Short | 17 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.52e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -3 % |
| Return on Assets (ttm) | 81.9 % |
| Return on Equity (ttm) | -49 % |
| Qtrly Rev. Growth | 305210 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -0.2 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -3 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 22420 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|